Pioneering studies and follow-up case series provide compelling evidence for the potential of CD19 targeting CAR T cell therapy to induce sustained remission in patients with refractory SLE, reframing the understanding and approach to treatment in autoimmune pathology. Here, CD19 is linked to systemic lupus erythematosus.